Pharmacological Management of Chronic Neuropathic Pain: Revised Consensus Statement from the Canadian Pain Society
Open accessThe DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Neuropathic pain (NeP), redefined as pain caused by a lesion or a disease of the somatosensory system, is a disabling condition that affects approximately two million Canadians. OBJECTIVE: To review the randomized controlled trials (RCTs) and systematic reviews related to the pharmacological management of NeP to develop a revised evidence‐based consensus statement on its management. METHODS: RCTs, systematic reviews and existing guidelines on the pharmacological management of NeP were evaluated at a consensus meeting in May 2012 and updated until September 2013. Medications were recommended in the consensus statement if their analgesic efficacy was supported by at least one methodologically sound RCT (class I or class II) showing significant benefit relative to placebo or another relevant control group. Recommendations for treatment were based on the degree of evidence of analgesic efficacy, safety and ease of use. RESULTS: Analgesic agents recommended for first‐line treatments are gabapentinoids (gabapentin and pregabalin), tricyclic antidepressants and serotonin noradrenaline reuptake inhibitors. Tramadol and controlled‐release opioid analgesics are recommended as second‐line treatments for moderate to severe pain. Cannabinoids are now recommended as third‐line treatments. Recommended fourth‐line treatments include methadone, anticonvulsants with lesser evidence of efficacy (eg, lamotrigine, lacos‐amide), tapentadol and botulinum toxin. There is support for some analgesic combinations in selected NeP conditions. CONCLUSIONS: These guidelines provide an updated, stepwise approach to the pharmacological management of NeP. Treatment should be individualized for each patient based on efficacy, side‐effect profile and drug accessibility, including cost. Additional studies are required to examine head‐to‐head comparisons among analgesics, combinations of analgesics, long‐term outcomes and treatment of pediatric, geriatric and central NeP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Results from both the scientific literature and public media revealed few references to nabilone abuse.”
From Nabilone for the Management of Pain (2016) · cites this paper as [32]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, nabilone theft did occur, although nabilone has no known street value.”
From Nabilone for the Management of Pain (2016) · cites this paper as [32]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“According to the literature, the positive side effects (euphoria, mood elevation) of nabilone, which may lead to abuse, generally occurred less frequently than the negative side effects (drowsiness, dizziness, and dry mouth).”
From Nabilone for the Management of Pain (2016) · cites this paper as [32]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the public media, patients described nabilone as not producing the same therapeutic and recreational effects as smoked cannabis.”
From Nabilone for the Management of Pain (2016) · cites this paper as [32]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Overall, the authors concluded that nabilone is rarely abused or diverted.”
From Nabilone for the Management of Pain (2016) · cites this paper as [32]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treede (2008) · doi:10.1212/01.wnl.0000282763.29778.59 · Cited by 2,746
Bouhassira, D., Attal, N., Alchaar, H., Boureau, F., Brochet, B., Bruxelle, J., Cunin, G., Fermanian, J., Ginies, P., Grun-Overdyking, A., et al. (2005) · Pain · doi:10.1016/j.pain.2004.12.010 · Cited by 2,741
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873 · cited 1×
“Another trial investigating venlafaxine plus SECOND-lINE ANAlgESICS”
Prevalence of chronic pain with neuropathic characteristics in the general population
Bouhassira, D., Lantéri-Minet, M., Attal, N., Laurent, B., & Touboul, C. (2008) · Pain · doi:10.1016/j.pain.2007.08.013 · Cited by 1,745
Algorithm for neuropathic pain treatment: An evidence based proposal
Finnerup, N. B., Otto, M., McQuay, H. J., Jensen, T. S., & Sindrup, S. H. (2005) · Pain · doi:10.1016/j.pain.2005.08.013 · Cited by 1,330
Effects of Desipramine, Amitriptyline, and Fluoxetine on Pain in Diabetic Neuropathy
Max, M. B., Lynch, S. A., Muir, J., Shoaf, S. E., Smoller, B., & Dubner, R. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205073261904 · Cited by 1,117 · cited 1×
“Two small RCTs demonstrated benefit from methadone in chronic NeP ( ,57) and survey data suggested efficacy in mixed NeP conditions (58).”
The evidence for pharmacological treatment of neuropathic pain
Finnerup, N. B., Sindrup, S. H., & Jensen, T. S. (2010) · Pain · doi:10.1016/j.pain.2010.06.019 · Cited by 1,045 · cited 4×
“Venlafaxine has shown efficacy in neuropathy (37) and mixed painful polyneuropathy (38) at doses of 150 mg to 225 mg daily.”
InfluentialSmith, E. M. L., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., Bressler, L. R., Fadul, C. E., Knox, C., Le-Lindqwister, N., et al. (2013) · JAMA · doi:10.1001/jama.2013.2813 · Cited by 1,014 · cited 1×
“Relative to the previous guidelines for management of NeP published in 2007 (9), duloxetine has been upgraded from a second-line to a first-line agent based on recent evidence of efficacy in the management of chemotherapy-induced painful neuropathy (35) in addition to previously established efficacy in painful diabeti…”
MethodTorrance, N., Smith, B. H., Bennett, M. I., & Lee, A. J. (2006) · The Journal of Pain · doi:10.1016/j.jpain.2005.11.008 · Cited by 1,000 · cited 1×
“However, newer studies using population-based questionnaires estimate a higher rate of 4% to 8% (6,7), which suggest that approximately two million Canadians experience this disabling condition.”
BackgroundA systematic review of antidepressants in neuropathic pain
McQuay, H. J., Tramér, M., Nye, B. A., Carroll, D., Wiffen, P. J., & Moore, R. A. (1996) · Pain · doi:10.1016/s0304-3959(96)03140-5 · Cited by 930 · cited 1×
“Pain Res Manag Vol 19 No 6 November/December 2014 332 and desipramine) are better tolerated than tertiary amine TCAs (amitriptyline and imipramine) with comparable analgesic efficacy (71).”
Research works printed but not linked: 1
- [20]Cohen J Statistical Power Analysis for the Behavioural Sciences New York, San Francisco, London Academic Press 1988
Cited by
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602
Colloca, L., Ludman, T., Bouhassira, D., Baron, R., Dickenson, A. H., Yarnitsky, D., Freeman, R., Truini, A., Attal, N., Finnerup, N. B., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.2 · Cited by 2,058
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Cannabis-based medicines for chronic neuropathic pain in adults
Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Häuser, W. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012182.pub2 · Cited by 571
Gabapentin for chronic neuropathic pain in adults
Wiffen, P. J., Derry, S., Bell, R. F., Rice, A. S., Tölle, T. R., Phillips, T., & Moore, R. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007938.pub4 · Cited by 561
Metadata
- Authors
- Moulin, D., Boulanger, A., Clark, A., Clarke, H., Dao, T., Finley, G., Furlan, A., Gilron, I., Gordon, A., Morley-Forster, P., Sessle, B., Squire, P., Stinson, J., Taenzer, P., Velly, A., Ware, M., Weinberg, E., & Williamson, O.
- Affiliations
- Victoria Hospital (CA)
- Corresponding author
- Moulin, DE
- Venue
- Pain Research and Management
- Publisher
- Wiley
- Published
- 2014-01
- Volume
- 19
- Issue
- 6
- Pages
- 328-335
- ISSN
- 1203-6765 (ISSN-L)
- 1918-1523
- PMC
- PMC4273712
- OpenAlex
- W2206489433
- Cited by
- 529
- References
- 97
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 54 · 2023: 38 · 2022: 38 · 2021: 58 · 2020: 53 · 2019: 53 · 2018: 52 · 2017: 60 · 2016: 50 · 2015: 43
- FWCI
- 34.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pain Research and Management (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship@McGill (McGill) (submittedVersion, cc-by)
- eScholarship@McGill (McGill) (submittedVersion, other-oa)
- Funders
- Neuropathic Pain Special Interest Group of the CPS
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- neuropathic pain, pharmacological management, gabapentinoids, pregabalin, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, tramadol, controlled-release opioids, cannabinoids, methadone, antiepileptic drugs, tapentadol, botulinum toxin, analgesic combination, stepwise treatment, analgesic efficacy and safety
- MeSH terms
- Analgesics, Canada, Humans, Neuralgia, Chronic Pain, Pain Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.